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Abstract
Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral cav-
ity and oropharynx, is a cause of substantial global morbidity and mortality. Strategies to
reduce disease burden include discovery of novel therapies and repurposing of existing
drugs. Statins are commonly prescribed for lowering circulating cholesterol by inhibiting
HMG-CoA reductase (HMGCR). Results from some observational studies suggest that
statin use may reduce HNSCC risk. We appraised the relationship of genetically-proxied
cholesterol-lowering drug targets and other circulating lipid traits with oral (OC) and oropha-
ryngeal (OPC) cancer risk using two-sample Mendelian randomization (MR). For the pri-
mary analysis, germline genetic variants in HMGCR, NPC1L1, CETP, PCSK9 and LDLR
were used to proxy the effect of low-density lipoprotein cholesterol (LDL-C) lowering
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Data Availability Statement: Summary-level
analysis was conducted using publicly available
GWAS data. Full summary statistics for the GAME-
therapies. In secondary analyses, variants were used to proxy circulating levels of other lipid
traits in a genome-wide association study (GWAS) meta-analysis of 188,578 individuals.
Both primary and secondary analyses aimed to estimate the downstream causal effect of
cholesterol lowering therapies on OC and OPC risk. The second sample for MR was taken
from a GWAS of 6,034 OC and OPC cases and 6,585 controls (GAME-ON). Analyses were
replicated in UK Biobank, using 839 OC and OPC cases and 372,016 controls and the
results of the GAME-ON and UK Biobank analyses combined in a fixed-effects meta-analy-
sis. We found limited evidence of a causal effect of genetically-proxied LDL-C lowering
using HMGCR, NPC1L1, CETP or other circulating lipid traits on either OC or OPC risk.
Genetically-proxied PCSK9 inhibition equivalent to a 1 mmol/L (38.7 mg/dL) reduction in
LDL-C was associated with an increased risk of OC and OPC combined (OR 1.8 95%CI 1.2,
2.8, p = 9.31 x10-05), with good concordance between GAME-ON and UK Biobank (I2 =
22%). Effects for PCSK9 appeared stronger in relation to OPC (OR 2.6 95%CI 1.4, 4.9) than
OC (OR 1.4 95%CI 0.8, 2.4). LDLR variants, resulting in genetically-proxied reduction in
LDL-C equivalent to a 1 mmol/L (38.7 mg/dL), reduced the risk of OC and OPC combined
(OR 0.7, 95%CI 0.5, 1.0, p = 0.006). A series of pleiotropy-robust and outlier detection meth-
ods showed that pleiotropy did not bias our findings. We found limited evidence for a role of
cholesterol-lowering in OC and OPC risk, suggesting previous observational results may
have been confounded. There was some evidence that genetically-proxied inhibition of
PCSK9 increased risk, while lipid-lowering variants in LDLR, reduced risk of combined OC
and OPC. This result suggests that the mechanisms of action of PCSK9 on OC and OPC
risk may be independent of its cholesterol lowering effects; however, this was not supported
uniformly across all sensitivity analyses and further replication of this finding is required.
Author summary
Author summary
This study aimed to determine if genetically-proxied cholesterol-lowering drugs (such
as statins which target HMGCR) and genetically-proxied circulating lipid traits (e.g., low-
density lipoprotein cholesterol) have a causal effect on oral and oropharyngeal cancer risk.
There was little evidence that genetically-proxied inhibition of HMGCR (target of statins),
NPC1L1 (target of ezetimibe) and CETP (target of CETP inhibitors) influences oral or
oropharyngeal cancer risk. Similarly, there was little evidence of an effect of circulating
lipid traits on oral or oropharyngeal cancer risk. We did find some evidence that geneti-
cally-proxied inhibition of PCSK9 increases, while lipid-lowering variants in LDLR reduce
oral and oropharyngeal cancer risk. Our findings suggest that the results of previous
observational studies examining the effect of statins on oral and oropharyngeal risk may
have been confounded. The mechanism of action of PCSK9 may be independent of cho-
lesterol-lowering, however further replication of this finding in other head and neck can-
cer datasets is required.
Introduction
Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral cavity
(OC) and oropharynx (OPC), is the sixth most common cancer in the world, with over
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550,000 new cases and 300,000 deaths annually [1, 2]. Despite some modest improvements in
the treatment of HNSCC, survival ranges between 19–59% at 10 years [3] and recurrence rates
remain high [4]. Patients often undergo a combination of surgery, radiotherapy and chemo-
therapy which can result in significant morbidity [5]. Established risk factors include smoking,
alcohol and human papilloma virus (HPV), the latter mainly linked with oropharyngeal cancer
[6, 7]. Given that in contemporary cohorts, around 70% of OPC cases (versus <5% of OC
cases) are HPV driven and often present in younger populations, oral and oropharyngeal
tumours are considered distinct disease entities, with different risk factor profiles [8]. Despite
smoking cessation, alcohol reduction measures and the implementation of HPV vaccination
in some areas, HNSCC remains a major global health problem [2]. Novel strategies for preven-
tion of HNSCC are required, in particular for those at high risk and one approach is to identify
novel risk factors which can be easily modified, for example by repurposing existing drugs [9].
Statins are one of the most commonly prescribed medications worldwide. They are pre-
scribed to reduce levels of circulating total and low-density lipoprotein cholesterol (LDL-C),
with proven preventative and therapeutic effects in cardiovascular disease and a good safety
profile [10, 11]. Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA
reductase (HMGCR)), the rate-limiting enzyme in the mevalonate pathway, responsible for
cholesterol and steroid hormone synthesis [12]. Other clinically approved drugs that target
cholesterol metabolism via different mechanisms include ezetimibe (targeting Niemann-Pick
C1-like protein (NPC1L1)) and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibi-
tors such as evolocumab or alirocumab. These agents act by reducing the intestinal absorption
of cholesterol or by enhancing uptake of LDL-C through increased cellular membrane expres-
sion of the LDL-receptor (LDLR), respectively. Conversely, cholesteryl ester transfer protein
inhibitors (CETP) substantially increase levels of high-density lipoprotein cholesterol
(HDL-C), lower levels of LDL-C and enhance reverse cholesterol transport [13].
Cholesterol is vital for a variety of key cellular functions, including membrane integrity, signal-
ling, protein synthesis and cell cycle progression. Therefore, modulation of cholesterol synthesis
has the potential to influence several hallmarks of tumourigenesis including cell migration and
proliferation [14]. In an experimental study, mice given oral daily doses of simvastatin two weeks
prior to subcutaneous injection of FaDu (HPV-negative hypopharyngeal tumour cells), showed a
significant reduction in tumour growth. This study was designed to mimic a clinical scenario
where patients who present with a tumour may have been taking the medication prior to tumour
initiation [15], and suggested that simvastatin antagonises tumour metabolic reprogramming,
another important hallmark of cancer [15]. Mechanistic support for the role of LDL-C lowering
in cancer development comes largely from the fact that lipids are themselves major cell mem-
brane components essential for cell division and maintaining tissue integrity. Changes in lipid
levels have been reported associated with tumour development [16, 17].
However, the evidence that cholesterol-lowering drugs may reduce the risk of head and
neck cancer in vivo is limited. Some observational studies report an inverse association of tak-
ing statins with both head and neck cancer risk [18] and cancer survival [14], but others indi-
cate little evidence of any effect on cancer [19]. Observational studies are not randomised and
are susceptible to reverse causality and/or confounding [19]. Mendelian randomization (MR)
is an approach that uses germline genetic proxies (referred to as instruments) to help appraise
causal effects of potentially modifiable extrinsic exposures or intrinsic traits with disease [20–
22]. It has also been used to estimate therapeutic potential by investigating genetic variation at
drug targets [23]. Numerous single nucleotide polymorphisms (SNPs) are associated with
lower levels of circulating LDL-C [24, 25] and inheriting an LDL-C lowering allele has been
proposed to be analogous to being assigned life-long treatment with a cholesterol lowering
drug [26]. In this way, germline genetic variants may serve as proxies for exposure to potential
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pharmacological agents which are less likely than observational measures to be subject to
reverse causation or confounding. Genetic proxies can therefore be used to predict both the
likely beneficial and adverse effects of long-term modulation of the drug targets on disease.
MR has previously demonstrated the protective effect of cholesterol-lowering drugs on car-
diovascular disease risk [27], but also that inhibition of HMGCR and PCSK9 may have an
adverse effect on diabetes risk [28]. Of relevance to cancer, some recent MR studies have
shown that genetically-proxied inhibition of HMGCR may be protective against overall cancer
[29] and epithelial ovarian cancer [30] risk. Our aim was to use MR to appraise the causal
nature and mechanistic basis of the relationship between cholesterol-lowering and risk of oral
and oropharyngeal cancer by investigating germline variation in HMGCR, NPC1L1, CETP,
PCSK9 and LDLR, and other related lipid traits such as circulating LDL-C.
Methods
Identifying cholesterol-lowering genetic instruments
For the primary analysis, SNPs in HMGCR, NPC1L1, CETP, PCSK9 and LDLR were used to
proxy the effect of lipid-lowering therapies and to estimate the downstream effect of manipu-
lating these targets on OC and OPC risk. SNPs were identified within 100 kb on either side of
the target gene (HMGCR, NPC1L1, CETP, PCSK9 and LDLR) that were associated with LDL-C
levels. Variants were robustly associated with LDL-C in a meta-analysis of genome-wide asso-
ciation studies (GWAS) involving 188,578 individuals primarily (96%) of European ancestry
in the Global Lipids Genetic Consortium (GLGC) [25]. As previously described by Ference
et al., SNPs were iteratively selected for inclusion in order of decreasing magnitude of associa-
tion (effect size) with LDL-C. All polymorphisms had a p-value for association with LDL-C of
<5 x10-8 and low linkage disequilibrium (LD) (defined as r2 <0.2) with all other SNPs that
were included in the score [28]. Multiple papers have used these genetic instruments at this
threshold, to demonstrate causal effects in cardiovascular disease [13, 27, 31], diabetes [28]
and ovarian cancer [30]. In secondary analyses, SNPs were used to proxy circulating levels of
LDL-C, HDL-C, total triglyceride, total cholesterol, apolipoprotein A and B. Betas represented
the change in lipid trait levels per copy of the effect allele. SNPs utilised in the secondary analy-
sis SNPs were already independently (r2 <0.001) associated with the respective traits in large
GWAS which have been described previously [25, 32].
Summary level genetic data on oral and oropharyngeal cancer from
GAME-ON
We estimated the effects of the cholesterol-lowering genetic variants on risk of OC and OPC
using GWAS performed on 6,034 cases and 6,585 controls from 12 studies which were part of
the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network [33]. The study
population included participants from Europe (45.3%), North America (43.9%) and South
America (10.8%). Cancer cases comprised the following the International Classification of Dis-
eases (ICD) codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9, C05.0-C06.9) orophar-
ynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9), overlapping (C14 and
combination of other sites) and 25 cases with unknown ICD code (other). A total of 954 indi-
viduals with cancers of hypopharynx, unknown code or overlapping cancers were excluded.
Genomic DNA isolated from blood or buccal cells was genotyped at the Center for Inherited
Disease Research (CIDR) using an Illumina OncoArray, custom designed for cancer studies
by the OncoArray Consortium [34]. In GAME-ON, all SNPs with a call rate of<95% were
excluded. Given the ethnic heterogeneity of the study population, the dataset was divided by
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geographical region and SNPs within each region that showed deviation from Hardy-Wein-
berg Equilibrium (HWE) in controls (p =<1 x10−7) were excluded. Principal component anal-
ysis (PCA) was performed using approximately 10,000 common markers in low LD (r2
<0.004), minor allele frequency (MAF) >0.05 and 139 population outliers were removed. Full
details of the included studies, as well as the genotyping and imputation performed, have been
described previously [33, 35].
Two-sample Mendelian randomization
Two-sample MR was conducted using the “TwoSampleMR” package in R (version 3.5.3), by
integrating SNP associations for cholesterol-lowering (sample 1) with those for OC and OPC
in GAME-ON (sample 2). For those SNPs instrumenting LDL-C lowering, we first extracted
summary statistics for the associations with OC and OPC from GAME-ON. We next per-
formed harmonisation of the direction of effects between the cholesterol-lowering exposures
and outcome (OC or OPC) where, for each variant, the allele designated the ‘exposure allele’
was associated with lower LDL-C levels and palindromic SNPs were aligned when MAFs were
<0.3 or were otherwise excluded. In our primary analysis, four palindromic SNPs, one in
HMGCR (rs2006760), the other in PCSK9 (rs2149041) and two in CETP (rs5880, rs9929488)
were removed. In the secondary analysis with other lipid traits, 11 palindromic SNPs
(rs1936800, rs2288912, rs7112577, rs964184, rs150617279, rs1883711, rs4722043, rs2156552,
rs2954029, rs581080, rs7534572) were removed.
Individual effect-estimates for each SNP were calculated using the Wald ratio, by dividing the
SNP-outcome association by the SNP-exposure association. Multiple SNPs were then combined
into multi-allelic instruments using the random-effects inverse-variance weighted (IVW) meta-
analysis method, for each of the genes HMGCR, NPC1L1, CETP, PCSK9 and LDLR. This meta-
analysis was undertaken to increase the proportion of variance in drug targets and LDL-C lower-
ing explained by each instrument, and thus improve statistical power and the precision of our
estimates [36]. The analysis produced an estimate of the effect of the risk factor on OC and OPC
risk. As the instruments for HMGCR, NPC1L1, CETP, PCSK9 and LDLR were in weak LD (r2
<0.2), we accounted for this correlation between SNPs in the primary analysis using LDlink (4.0
Release) which employs Phase 3 (Version 5) of the 1000 Genomes Project and variant rs numbers
based on dbSNP [37]. Correlation matrices were inserted as an MRInput object, resulting in MR
methods which altered the weightings for correlated SNPs [38–40]. For circulating lipid traits, a
more stringent r2<0.001 was already applied in the initial GWAS [25], so we did not account
further for correlation in the secondary analysis. We computed odds ratios (OR) which represent
the change in odds of oral and oropharyngeal squamous cell carcinoma per genetically-proxied
inhibition of the drug target, equivalent to a 1 mg/dl decrease in LDL-C. The OR was scaled to be
per 1 mmol/L decrease by dividing the LDL-C lowering effect (beta) and standard error (se) mea-
sured in mg/dL by 38.7 [30]. The betas and standard errors for HMGCR, NPC1L1, CETP, PCSK9
and LDLR SNPs were also converted to reflect the cholesterol-lowering effect, given the “Two-
SampleMR” package preference to automatically change these into a positive direction of effect
(i.e., lipid increasing). The correct direction of effect was checked using a positive control of coro-
nary heart disease from the CARDIoGRAM GWAS data [41]. MR was also used to examine the
effect of circulating levels of LDL-C, HDL-C, total triglyceride, total cholesterol, apolipoprotein A
and B levels directly with OC and OPC cancer risk. The ORs in this analysis represent the change
in odds of oral or oropharyngeal squamous cell carcinoma, per SD unit increase in lipid trait.
The IVW method can provide an unbiased effect estimate in the absence of horizontal pleiot-
ropy or when horizontal pleiotropy is balanced [42]. We therefore performed sensitivity analyses
to evaluate the potential for unbalanced horizontal pleiotropy, where genetic variants influence
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two or more traits through independent biological pathways. To ensure the genetic instrument
was associated with the instrument it was proxying, estimates of the proportion of variance in
each risk factor explained by the instrument (R2) and F-statistics were generated. An F-statistic of
<10 is indicative of a weak instrument which may be subject to weak instrument bias. To account
for directional pleiotropy, we compared the IVW results with three MR sensitivity analyses,
which each make different assumptions: MR Egger [43], weighted median [44] and weighted
mode [45]. While these three methods are best used when genetic instruments consist of a large
numbers of independent SNPs, since r2 values between SNPs in our instruments were low (r2
<0.2), we a-priori decided to include them, with a further sensitivity analysis to account for corre-
lation in the MR Egger analysis. The weighted median stipulates that at least 50% of the weight in
the analysis stems from variants that are valid instruments [44], while the weighted mode requires
that the largest subset of instruments which identify the same causal effect to be valid instruments
[45]. MR-Egger can provide unbiased estimates even when all SNPs in an instrument violate the
exclusion restriction assumption (i.e., affect the outcome by means other than via the risk factor
of interest). However, there must be negligible measurement error (NOME) [46] in the genetic
instrument and the InSIDE (Instrument Strength Independent of Direct Effect) assumption must
be satisfied [43]. Where there was evidence of violation of the NOME assumption, this was
assessed using the I2 statistic and MR-Egger was performed with simulation extrapolation
(SIMEX) correction [46]. To further assess the robustness of findings, we examined evidence of
heterogeneity in the individual SNP estimates using the Cochran Q-statistic, which may indicate
the presence of invalid instruments (e.g., due to horizontal pleiotropy) [47]. Scatter and leave-
one-out plots were produced to evaluate influential outliers and MR-PRESSO (Mendelian Ran-
domization Pleiotropy RESidual Sum and Outlier) was used to detect and correct for potential
outliers (where Q-statistic p<0.05) [48]. For any positive findings, we ran colocalisation analysis
using the ‘coloc’ package in R [49], to test if there was violation of the MR exclusion restriction
assumption. This can be generated through instrument-exposure and instrument-outcome asso-
ciations, driven by distinct causal variants that are in LD with each other. The ‘coloc’ package in R
enumerates every possible configuration of causal variants for two traits, calculating the support
for that causal model in the form of a Bayes factor, assuming that at most one causal variant per
trait exists in the region and there are similar LD structures across the two samples. Approximate
Bayes factor colocalisation analysis fine maps each trait under a single causal variant assumption
and then integrates these over two posterior distributions to estimate probabilities that those vari-
ants are shared [49]. A posterior probability of� 0.80 is considered evidence to support a particu-
lar configuration tested in ‘coloc’. Using genomic regions of 1 Mb either side of the lead variant
for the genes of interest, we investigated whether findings reflect shared causal variants.
Stratification by cancer subsite
Given the difference in established aetiology (i.e. smoking, alcohol and HPV) at each HNSCC
subsite [6], we performed MR analyses with stratification by cancer subsite to evaluate poten-
tial heterogeneity in effects. For this, we used GWAS summary data on a subset of 2,641 OPC
cases and 2,990 OC cases from the 6,034 HNSCC cases and the 6,585 common controls in the
GAME-ON GWAS [33].
Replication in UK Biobank
UK Biobank data was used as a replication dataset for primary analyses. A GWAS was per-
formed on 839 combined OC and OPC cases and 372,016 controls, with two further stratified
GWAS for OC (n = 357) and OPC (n = 494). UK Biobank is a large population-based cohort
study that recruited over 500,000 men and women aged between 37 and 73 years between
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2006 and 2010 throughout the UK. It received ethical approval from the National Health Ser-
vice North West Centre for Research Ethics Committee (reference: 11/NW/0382). Details of
genotyping quality control, phasing and imputation are described elsewhere [50]. Participant
records are linked to cancer registry data and HNSCC was grouped using the same ICD-codes
as described above. Squamous cell carcinoma cases were identified using histology codes
8070–8078. UK Biobank GWAS analyses were adjusted for sex and genotyping array and per-
formed in BOLT-LMM, a mixed model that accounts for population stratification and related-
ness [51, 52]. Primary MR analyses as described above in GAME-ON were repeated in UK
Biobank data.
Meta-analysis of results
We performed both fixed-effects and random-effects meta-analysis of the MR estimates in
GAME-ON and UK Biobank using the R package ‘meta’. However, we focus more on the
fixed-effects estimates since we assume that the causal effect is constant between the studies
[53]. Heterogeneity between study populations was assessed using I2 statistic [54].
Results
Primary analysis in GAME-ON
In total, 5 SNPs in HMGCR (rs12916, rs17238484, rs5909, rs2303152, rs10066707) were used
to proxy HMG-CoA reductase inhibition (statins); 5 SNPs in NPC1L1 (rs217386, rs2073547,
rs7791240, rs10234070, rs2300414) proxied NPC1L1 inhibition (ezetimibe); 6 SNPs in CETP
(rs9989419, rs12708967, rs3764261, rs1800775, rs1864163, rs289714) proxied CETP inhibition;
6 SNPs in PCSK9 (rs11206510, rs2479409, rs2479394, rs10888897, rs7552841, rs562556) prox-
ied PCSK9 inhibition; 3 SNPs proxied cholesterol-lowering in LDLR (rs6511720, rs1122608,
rs688) (LDL-receptor inhibition). Further details of these SNP effects are given in Table 1.
There was limited evidence of an effect of genetically-proxied inhibition of HMGCR and
NPC1L1 on combined OC and OPC risk (OR IVW 1.1; 95%CI 0.6, 1.9, p = 0.82 and 1.0; 95%
CI 0.4, 2.7, p = 0.99), respectively (Table 2 and S1 Fig). A similar result was found for geneti-
cally-proxied LDL-C lowering inhibition of CETP on OC and OPC combined (OR IVW 1.3;
95%CI 0.6, 2.6, p = 0.49) (Table 2 and S1 Fig). However, higher risk of combined OC and
OPC was found in relation to genetically-proxied PCSK9 inhibition, equivalent to a 1 mmol/L
(38.7 mg/dL) reduction in LDL-C (OR IVW 2.1; 95%CI 1.2, 3.4, p = 0.01; Table 2 and Fig 1).
This is in contrast to the reduction in odds seen in relation to cardiovascular disease using the
same instrument (OR IVW 0.6; 95%CI 0.4, 0.8, p<1 x10-03; Fig 2) in 60,801 cases and 123,504
control subjects enrolled in the CARDIoGRAM consortia studies [41]. There was also some
evidence that LDLR variants, resulting in genetically-proxied reduction in LDL-C equivalent
to a 1 mmol/L (38.7 mg/dL), reduced the risk of combined OC and OPC (OR IVW; 0.7; 95%
CI 0.4, 1.0, p = 0.05; Table 2 and Fig 1). The combined OC/OPC results were robust to multi-
ple testing in the main analysis conducted (i.e., IVW for the drug targets = p<0.05/5 = 0.001).
Stratification by cancer subsite in GAME-ON
When stratified by subsite, the adverse effect of PCSK9 appeared to be mainly in the orophar-
ynx, (OR IVW 3.5; 95%CI 1.6, 7.7, p = 2 x10-03), with limited evidence in the oral cavity (OR
IVW 1.6; 0.9, 2.94, p = 0.11) (Table 2 and Fig 1). The effects appeared stronger in OPC versus
OC, but with overlapping confidence intervals. LDLR was associated with a reduction in risk
of OC (OR IVW 0.5; 95%CI 0.3, 0.9, p = 0.01), but there was little evidence of an association
with OPC (OR IVW 0.9; 95%CI 0.5, 1.5, p = 0.69) (Table 2 and Fig 1). For both PCSK9 and
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LDLR associations, the direction of effect was generally consistent across the four MR methods
tested (Table 2).
Secondary analysis in GAME-ON
SNPs were also used to proxy circulating levels of LDL-C (77 SNPs), high-density lipoprotein
cholesterol (HDL-C) (85 SNPs), total triglyceride (54 SNPs), total cholesterol (82 SNPs), apoli-
poprotein A (9 SNPs) and apolipoprotein B (14 SNPs) (S1 Table). There was limited evidence
of an effect of any of these other lipid traits on either OC or OPC (Table 3 and S2 Fig).
Sensitivity analyses
IVW, MR Egger, weighted median, simple and weighted mode were carried out, in addition to
IVW analysis accounting for LD structure (S2 Table). The results adjusting for SNP
Table 1. Detailed summary of LDL-C lowering genetic variants in HMGCR, NPC1L1, CETP, PCSK9 and LDLR variants from the in Global Lipids Genetics Consor-
tium (GLGC).
Target SNP Pathway EA OA EAF Beta se P-value
HMGCR rs12916 LDL-C T C 0.57 -0.06061 0.003 7.79E-78
rs17238484 LDL-C G T 0.75 -0.05184 0.005 1.35E-21
rs5909 LDL-C G A 0.90 -0.05102 0.007 4.93E-13
rs2303152 LDL-C G A 0.88 -0.03498 0.005 1.04E-09
rs10066707 LDL-C G A 0.58 -0.0411 0.005 2.97E-19
rs2006760� LDL-C C G 0.81 -0.04407 0.006 1.67E-13
NPC1L1 rs217386 LDL-C A G 0.41 -0.02908 0.003 1.20E-19
rs2073547 LDL-C A G 0.81 -0.03885 0.004 1.92E-21
rs7791240 LDL-C T C 0.91 -0.03404 0.005 1.84E-10
rs10234070 LDL-C C T 0.90 -0.02363 0.005 1.52E-06
rs2300414 LDL-C G A 0.93 -0.02828 0.006 5.45E-06
CETP rs3764261 LDL-C A C 0.29 -0.04471 0.004 2.22E-34
rs1800775 LDL-C A C 0.48 -0.03487 0.003 8.54E-24
rs1864163 LDL-C G A 0.73 -0.03698 0.004 7.97E-21
rs9929488� LDL-C G C 0.70 -0.03159 0.004 8.15E-13
rs9989419 LDL-C G A 0.60 -0.02344 0.004 2.49E-12
rs12708967 LDL-C T C 0.80 -0.02963 0.004 3.47E-11
rs289714 LDL-C A G 0.79 -0.03032 0.005 2.85E-10
rs5880� LDL-C G C 0.94 -0.03979 0.008 1.59E-06
PCSK9 rs11206510 LDL-C C T 0.15 -0.06871 0.001 2.38E-53
rs2479409 LDL-C A G 0.67 -0.05309 0.001 2.52E-50
rs2149041� LDL-C C G 0.84 -0.05259 0.001 1.44E-35
rs2479394 LDL-C A G 0.72 -0.03192 0.001 1.58E-19
rs10888897 LDL-C T C 0.40 -0.04192 0.001 8.43E-31
rs7552841 LDL-C C T 0.63 -0.04589 0.001 5.40E-15
rs562556 LDL-C G A 0.19 -0.05292 0.002 6.16E-21
LDLR rs6511720 LDL-C T G 0.11 -0.17482 0.004 3.69E-54
rs1122608 LDL-C T G 0.23 -0.05473 0.003 2.02E-86
rs688 LDL-C C T 0.56 -0.04465 0.003 3.04E-48
Abbreviations: EA, effect allele or low-density lipoprotein-cholesterol (LDL-C) lowering allele; OA = other or non-effect allele; EAF, effect allele frequency; se = standard
error.
� Palindromic SNPs removed. Beta represents the change in LDL-C levels per copy of the effect allele. For SI conversion of mmol/L to mg/dL, multiply by 38.7.
https://doi.org/10.1371/journal.pgen.1009525.t001
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correlation followed the same pattern as the main results (S3 Table). There was limited evi-
dence of weak instrument bias being present (F-statistic >10) and the proportion of variance
in the phenotype (R2) explained by the genetic instruments ranged from 0.1 to 6% (S4 Table).
Table 2. Mendelian randomization results of genetically-proxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and LDLR with risk of oral and oropharyngeal
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Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; P, p-value.
OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma per genetically-proxied inhibition of drug target equivalent to a 1 mmol/
L decrease in LDL-C.
https://doi.org/10.1371/journal.pgen.1009525.t002
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In both primary and secondary analyses there was limited evidence of heterogeneity in the
SNP effect estimates for IVW and MR Egger regression, except for in HDL-C (Q IVW 115.7,
p = 0.01; Q MR Egger 115.6, p = 0.01) (S5 and S6 Tables).
MR Egger intercepts also indicated limited evidence of directional pleiotropy (S7 and S8
Tables). There were no clear outliers in both scatter and leave-one-out plots (Figs 3 and S3-
S6) and MR-PRESSO detected no individual outliers (S9 Table). Where there was evidence of
violation of the NOME assumption for the HMGCR, NPC1L1 and CETP instruments (i.e., I2
statistic <0.90) (S10 Table), MR-Egger was performed with SIMEX correction and effects
were still consistent with the null (S11 Table). To further investigate whether the positive find-
ings for PCSK9 and LDLR are due to violation of the exclusion restriction assumption, coloca-
lisation analysis was carried out [49]. This showed no conclusive evidence of shared causal
variants between LDL-C and oral/oropharyngeal cancer, with posterior probabilities of 0.055
for PCSK9 and 0.026 for LDLR, respectively (S12 Table).
Fig 1. Forest plot showing the causal effects of HMGCR, NPC1L1, CETP, PCSK9 and LDLR variants on the oral
and oropharyngeal cancer subsites in GAME-ON. Effect estimates on oral and oropharyngeal cancer are reported on
the log odds scale.
https://doi.org/10.1371/journal.pgen.1009525.g001
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Replication in UK Biobank and meta-analysis of results
Primary MR analyses as described above were replicated in UK Biobank, showing limited evi-
dence of an effect of genetically-proxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and
LDLR on risk of OC and OPC (S13 Table). Following IVW fixed-effects meta-analysis of
GAME-ON and UK Biobank MR results, there was a consistently strong effect of genetically-
proxied PCSK9 inhibition on combined OC and OPC (OR IVW 1.8; 95%CI 1.2, 2.8), with
good concordance between studies (I2 = 22%) and methods used (Figs 4 and S7). Effects for
PCSK9 appeared stronger in relation to OPC (OR IVW 2.6; 95%CI 1.4, 4.9) than OC (OR
IVW 1.4; 95%CI 0.8, 2.4), but with moderate heterogeneity between studies (I2 = 41%) (Fig 4).
Conversely, the protective effect for LDLR on OC and OPC combined was also consistent in
the meta-analysis (OR IVW 0.7; 95%CI 0.5, 1.0), with good concordance between studies (I2 =
0%) (Figs 5 and S7). However, the protective effect seen specifically in relation to OC in
GAME-ON (OR IVW 0.5; 95%CI 0.3, 0.9) was not replicated in UK Biobank (OR IVW 1.6;
95%CI 0.5, 4.8), with strong evidence of heterogeneity between the studies (I2 = 66%).
Discussion
We found limited evidence for a role of cholesterol-lowering in OC and OPC risk. This
included the absence of a protective effect of genetically-proxied inhibition of HMGCR, sug-
gesting previous observational studies investigating the relationship between statins and head
and neck cancer risk may be subject to residual confounding or bias. However, we did observe
an adverse effect of PCSK9 inhibition on OC and OPC risk, which was of a similar magnitude
Fig 2. Forest plots showing the causal effects of cholesterol-lowering PCSK9 and LDLR single nucleotide
polymorphisms on coronary heart disease and combined oral/ oropharyngeal cancer in GAME-ON. Effect
estimates on oral and oropharyngeal cancer are reported on the log odds scale.
https://doi.org/10.1371/journal.pgen.1009525.g002
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Table 3. Mendelian randomization results of circulating lipid traits with risk of oral and oropharyngeal cancer in GAME-ON.
Target N SNPs Outcome IVW OR (95% CI) P-value
LDL-C 77 Oral/ Oropharyngeal cancer 0.98 (0.87, 1.11) 0.79
Oral cancer 0.99 (0.85, 1.15) 0.88
Oropharyngeal cancer 1.03 (0.87, 1.21) 0.76
HDL-C 85 Oral/ Oropharyngeal cancer 0.98 (0.83, 1.16) 0.79
Oral cancer 1.08 (0.88, 1.32) 0.45
Oropharyngeal cancer 0.87 (0.71, 1.05) 0.15
Total triglycerides 54 Oral/ Oropharyngeal cancer 1.19 (1.01, 1.04) 0.04
Oral cancer 1.19 (0.96, 1.46) 0.11
Oropharyngeal cancer 1.19 (0.96, 1.47) 0.12
Total cholesterol 82 Oral/ Oropharyngeal cancer 1.04 (0.91, 1.18) 0.55
Oral cancer 1.09 (0.93, 1.28) 0.30
Oropharyngeal cancer 1.00 (0.84, 1.20) 0.96
Apolipoprotein A 9 Oral/ Oropharyngeal cancer 0.87 (0.73, 1.03) 0.11
Oral cancer 0.90 (0.73, 1.12) 0.34
Oropharyngeal cancer 0.82 (0.65, 1.04) 0.10
Apolipoprotein B 14 Oral/ Oropharyngeal cancer 1.04 (0.88, 1.22) 0.67
Oral cancer 1.15 (0.89, 1.49) 0.29
Oropharyngeal cancer 1.00 (0.83, 1.21) 0.98
Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals.
IVW OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma per SD increase in the circulating lipid trait (one SD for
LDL-C = 38.7 mg/dL, HDL-C = 15.5 mg/dL, Apolipoprotein A = 0.32 g/L, Apolipoprotein B = 0.52 g/L, Total triglycerides = 90.7 mg/dL, Total cholesterol = 41.8 mg/
dL).
https://doi.org/10.1371/journal.pgen.1009525.t003
Fig 3. Scatter plots for LDLR and PCSK9 single nucleotide polymorphisms effect on combined oral/
oropharyngeal cancer in GAME-ON.
https://doi.org/10.1371/journal.pgen.1009525.g003
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to the protective effect seen in relation to cardiovascular disease using the same genetic instru-
ment (Fig 2). This PCSK9 effect was evident in both the GAME-ON (n = 6,034 OC and OPC
cases and n = 6,585 controls) and UK Biobank datasets (n = 839 OC and OPC cases and
n = 372,016 controls). We also found some evidence for a protective effect of cholesterol-low-
ering variants in LDLR on OC and OPC risk in both studies. The IVW analysis for HMGCR,
NPC1L1, CETP, PCSK9 and LDLR accounting for LD structure followed the same pattern as
the main results (S3 Table). Further colocalisation analysis for PCSK9 and LDLR showed no
conclusive evidence of shared causal variants between LDL-C and oral and oropharyngeal
Fig 4. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering PCSK9 single nucleotide polymorphisms on
head and neck cancer subsites.
https://doi.org/10.1371/journal.pgen.1009525.g004
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cancer; however, the outcome dataset had a relatively smaller sample size, and typically large
sample sizes are required across both traits for better accuracy (S12 Table) [49, 55].
Association between PCSK9, LDLR and cancer risk
Despite the lack of consistent evidence for a role of cholesterol-lowering on risk of OC or OPC
in this study, individual effects of both PCSK9 and LDLR were demonstrated which may
implicate a role for these drug targets in the development of OC or OPC via other mechanisms.
Fig 5. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering LDLR single nucleotide polymorphisms on
head and neck cancer subsites.
https://doi.org/10.1371/journal.pgen.1009525.g005
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The effects identified in the present study are directionally consistent with a recent MR analy-
sis of 1,615 combined head and neck cancer cases from UK Biobank, which also found that a 1
SD unit increase in LDL-C proxied by PCSK9 and LDLR was associated with a reduction (OR
0.7 95%CI 0.4, 1.4, p = 0.35) and increase in odds (OR 1.6 95%CI 1.0, 2.4, p = 0.05) of head
and neck cancer, respectively [29]. The opposing effects of PCSK9 and LDLR in this study also
suggests that cholesterol lowering is unlikely to be the main mechanism of action. However,
this previous analysis is limited by the relatively small number of cases and heterogeneity of
head and neck cancer subtypes, with no selection for the histological subtype of squamous cell
carcinoma. In the present study, we focused specifically on oral and oropharyngeal subtypes of
HNSCC.
Beyond the established role of PCSK9 in cholesterol homeostasis, other potential pleiotropic
effects are not well understood. Variants in PCSK9 have been associated with an increased risk
of diabetes (OR 1.1, 95%CI 1.0, 1.2 for each 10 mg per decilitre decrease in LDL-C) [28]. How-
ever, a recent phenome-wide association study (PheWAS) did not find PCSK9 or LDLR to be
correlated with any non-lipid-related phenotypes, including diabetes [56]. There is limited in
vivo and in vitro evidence that PCSK9 might be involved in both cell proliferation and apopto-
sis. The gene was initially designated as NARC1 (neural apoptosis-regulated convertase 1),
involved in apoptosis of cerebellar neurons [57] and PCSK9 has since been found to be upregu-
lated in some cancers [58, 59].
One suggested mechanism for a link with cancer progression is that the increased expres-
sion of PCSK9 prevents LDL-receptor (LDLR) recycling, leading to hypercholesterolaemia and
more exogenous lipid to support the proliferation of the tumour [57]. Our study suggests the
opposite, that genetically-proxied inhibition of PCSK9 results in an increased risk of OC or
OPC. We hypothesise that access to intracellular LDL-C could in fact be pro-tumourigenic,
providing a favourable environment for a developing tumour cell, maintaining membrane
integrity and promoting cell division. Therapies such as statins, ezetimibe, and PCSK9 inhibi-
tors may all lower LDL-C level through the upregulation of LDL-receptors, resulting in ele-
vated intracellular cholesterol. However, cancer mechanisms are often context dependent and
perhaps only the expression of PCSK9 and LDLR is relevant in head and neck cancer. CETP
inhibitors instead block the transfer of cholesteryl ester from HDL-C to LDL-C, thereby rais-
ing HDL-C and lowering LDL-C (and apolipoprotein B), as well as enhancing reverse choles-
terol transport [60]. Unlike statins, CETP inhibitors do not appear to increase the risk of type
2 diabetes, thought to be as a result of pancreatic islet cell cholesterol accumulation with use of
other cholesterol-lowering drugs [61]. Therefore, the absence of effect when proxying CETP
inhibition in this study, supports the possible mechanism of LDL-C uptake via the LDL-recep-
tor in OC or OPC.
While both PCSK9 [62] and LDLR [62] are expressed in head and neck tumours, this was
not evident in normal oral or oropharyngeal tissue, and sufficient tissue is currently not avail-
able in expression datasets [63]. Recent studies have associated elevated PCSK9 with alcohol
use disorder, including the interesting possibility of using anti-PSCK9 monoclonal antibodies
for the treatment of alcoholic liver disease [64, 65]. Given that alcohol is a well-known risk fac-
tor for HNSCC, this pleiotropy could have partially explained the effect seen in our study,
however we proxied the inhibition of PCSK9 and so would have expected to see a protective
effect of this gene in HNSCC cases who may have been heavy alcohol drinkers. Further investi-
gation is required to untangle the relationship between PCSK9, alcohol and head and neck can-
cer, including a subsequent multivariable MR analysis.
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Comparison with previous studies
It is believed that statins could play a potential role in cancer chemoprevention which may
reduce the risk of some site-specific cancers such as prostate [66] and ovarian [30], but not all.
Some of these studies have reported cancer risk reductions by as much as 50–65% [67–69].
However, meta-analyses and clinical trials have contradicted these findings [70, 71]. In addi-
tion to confounding, immortal time bias may have inflated observational results because, to be
classified as a long-term statin user necessitates that users survived without cancer over a long
period [19, 72]. Dickerman et al. used electronic records from 733,804 adults with 10-year fol-
low-up to emulate a trial design. To achieve this a pre-specified protocol was set, including eli-
gibility criteria and checks were made to ensure effect estimates for statins on cancer were
comparable between the large observational dataset and trial. The authors found little indica-
tion that statin therapy influences cancer incidence, which was consistent with the analyses of
randomised trials (with a 10-year cancer-free survival difference of −0.3% 95%CI −1.5%, 0.5%)
[19]. Nonetheless, recent MR studies [29, 30] have identified an association between variants
in HMGCR with cancer risk, but not alternative cholesterol-lowering treatments or geneti-
cally-predicted LDL-C, suggesting that statins may reduce cancer risk through a cholesterol
independent pathway. A recent case-control study of over 11,000 participants found an inverse
association between statin use and the occurrence of HNSCC (OR 0.86, 95%CI 0.77, 0.95, p =
<0.01, of prior statin exposure for cases compared to propensity score-matched controls) [18].
However, this observational study failed to stratify by anatomical subsite, which may have
revealed distinct associations given differences in aetiology (e.g., the strong association of HPV
infection with OPC). Furthermore, a wider systematic review found that the evidence for the
role of statins in the prevention of HNSCC was limited [73]. As HNSCC incidence is a rare
outcome, randomised controls trials are not feasible, so we must be cautious interpreting the
available observational findings given the potential for bias and confounding as discussed
previously.
In contrast to previous MR studies assessing overall cancer risk [29] and ovarian specific
risk [30], the MR carried out here in relation to OC and OPC showed no effect using genetic
instruments for HMGCR (statins). There was also limited evidence for a causal effect of
NPC1L1 (ezetimibe), CETP (CETP inhibitors) as well as a number of other circulating lipid
traits on OC or OPC. Therefore, it remains unclear as to whether the effects observed with
PCSK9 and LDLR are via LDL-C lowering or another less well-established pathway [74, 75],
such as receptor regulation for viral entry, synthesis of sex hormones and resultant dysregu-
lated metabolism [76–78].
Strengths and limitations of this study
Protective associations between cholesterol-lowering therapies such as statins and head and
neck cancer risk seen in previous observational studies could be a result of reverse causation,
immortal time bias, lack of randomisation or confounding by socioeconomic status, smoking
or HPV infection, for example. Our study applied MR in an attempt to overcome these issues,
using the largest number of SNPs identified from the latest GWAS for both cholesterol-lower-
ing and head and neck cancer that could be identified in the literature [25, 33]. A series of plei-
otropy-robust MR methods and outlier detection were also applied to rigorously explore the
possibility that findings were not biased as a result of pleiotropy. However, there was no HPV
data available in these summary results to enable more detailed stratified analysis of OPC. We
did replicate findings for PCSK9 and LDLR, but the number of cases are low. Finally, most
participants in the GAME-ON network [33] were of European or North American decent,
with only around 11% from South America, and participants included in the UK Biobank
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analysis were exclusively of European descent, so more work is required to determine if our
results translate to other ancestry groups.
In conclusion, our MR analyses provided little evidence for a role of cholesterol lowering in
OC or OPC risk although effects of genetically-proxied inhibition of PCSK9 and cholesterol-
lowering variants in LDLR were observed in relation to OPC and OC risk. Given the lack of a
common pathway to carcinogenesis in OC or OPC, identifying metabolic targets that may be
common to all tumours, regardless of the activated molecular pathway, could help simplify a
preventative or therapeutic approach [79]. Replication of our findings in other head and neck
cancer datasets and use of individual-level follow-up data with HPV status could provide fur-
ther insight into the effect of these genetic instruments on risk, treatment outcomes and sur-
vival in head and neck cancer.
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